金吾财讯 | 葛兰素史克(GSK)声明其与美国生物科技公司Alector(ALEC)合作的试验性药物latozinemab未能延缓痴呆症进展，宣告又一款潜在痴呆症治疗药物研发失败。这款药物由Alector公司研发，针对的是一种名为“额颞叶痴呆”的痴呆症类型。葛兰素史克表示将终止该临床试验并分析结果。Alector周二表示，其试验性药物在一项晚期临床试验中未能减缓一种罕见痴呆症的进展，促使该公司终止了这项研究，并裁减了近一半的员工。
金吾财讯 | 葛兰素史克(GSK)声明其与美国生物科技公司Alector(ALEC)合作的试验性药物latozinemab未能延缓痴呆症进展，宣告又一款潜在痴呆症治疗药物研发失败。这款药物由Alector公司研发，针对的是一种名为“额颞叶痴呆”的痴呆症类型。葛兰素史克表示将终止该临床试验并分析结果。Alector周二表示，其试验性药物在一项晚期临床试验中未能减缓一种罕见痴呆症的进展，促使该公司终止了这项研究，并裁减了近一半的员工。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.